Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
review
OA: gold
CC0
⤵ 12 in-corpus citations
Abstract
Endometriosis is a chronic disease, in which endometrial-like tissue is found outside the uterine cavity. Lesions are typically located in the true pelvis but can be found, in addition to extragenital endometriosis, in the respiratory system, the diaphragm, the pleura or the pericardium. As the extrauterine endometrial lesions undergo the menstrual cycle, they cause many symptoms, including pain, and besides infertility, they all mostly affect the quality of the patient's life. Pharmacological management of endometriosis significantly increases in importance either as a first-line treatment or as a complementary therapy after surgery. Yet, current research on antagonists of the gonadotropin-releasing hormone (GnRH) has revealed their potential benefits in endometriosis treatment. Their mechanism of action is to down-regulate the hypothalamic-pituitary-gonadal axis and therefore induce a hypoestrogenic state. The resulting reduction of estrogen levels prevents disease progression and diminishes the recurrence rate after surgical removal of endometriosis. The present review summarizes recent reports of the role oral GnRH antagonists have as a significant treatment option for pain reduction in endometriosis patients.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (84)
- Adaptation linguistique de l’endometriosis health profile 5 : EHP 5 via openalex
- Adolescent Endometriosis: An Update via openalex
- Advanced indications for gonadotropin-releasing hormone (GnRH) analogues in gynecological oncology (Review) via openalex
- A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes via openalex
- Clinical diagnosis of endometriosis: a call to action via openalex
- Clinical Management of Endometriosis via openalex
- Clinical Management of Endometriosis via openalex
- Development of the Short Form Endometriosis Health Profile Questionnaire: The EHP-5 via openalex
- Diagnosis of endometriosis in the 21st century via openalex
- Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex
- Effect of GnRH analogues on apoptosis and release of interleukin-1 and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis via openalex
- [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis]. via openalex
- Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study via openalex
- Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies via openalex
- Elagolix: First Global Approval via openalex
- Elagolix for endometriosis: all that glitters is not gold via openalex
- Elagolix in endometriosis via openalex
- Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study via openalex
- Emerging therapies for endometriosis via openalex
- Endometriosis and Risk of Coronary Heart Disease via openalex
- Endometriosis in the male. via openalex
- Epigenetics of Estrogen and Progesterone Receptors in Endometriosis via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- Estrogen and progestogen receptor positive endometriotic lesions and disseminated cells in pelvic sentinel lymph nodes of patients with deep infiltrating rectovaginal endometriosis: a pilot study via openalex
- Highlights on Medical Treatment of Uterine Fibroids via openalex
- Long-Term Outcomes of Elagolix in Women With Endometriosis via openalex
- Measuring health-related quality of life in women with endometriosis: comparing the clinimetric properties of the Endometriosis Health Profile-5 (EHP-5) and the EuroQol-5D (EQ-5D) via openalex
- Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire via openalex
- Novel pharmacological therapies for the treatment of endometriosis via openalex
- Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) via openalex
- Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting via openalex
- Pathogenesis and pathophysiology of endometriosis via openalex
- Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review via openalex
- Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study via openalex
- Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis via openalex
- Structural and molecular features of the endomyometrium in endometriosis and adenomyosis via openalex
- Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain via openalex
- The Burden of Endometriosis on Women’s Lifespan: A Narrative Overview on Quality of Life and Psychosocial Wellbeing via openalex
- Theories of endometriosis via openalex
- Translation and validation of the Endometriosis Health Profile (EHP-5) in patients with laparoscopically diagnosed endometriosis via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study via openalex
- Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial via openalex
- Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration via openalex
- Vascular endothelial growth factor and endometriotic angiogenesis via openalex
- W6809509812 via openalex
- W1976877206 via openalex
- W1996855651 via openalex
- W1997957784 via openalex
- W2004430776 via openalex
- W2010587851 via openalex
- W2038221637 via openalex
- W2070378389 via openalex
- W2075947961 via openalex
- W2102100154 via openalex
- W2119501943 via openalex
- W2123704253 via openalex
- W2136453695 via openalex
- W2138336325 via openalex
- W2140139647 via openalex
- W2140246703 via openalex
- W2163315477 via openalex
- W2165510178 via openalex
- W2166230989 via openalex
- W2169701848 via openalex
- W2195249017 via openalex
- W2412965617 via openalex
- W2765174790 via openalex
- W2914196959 via openalex
- W2990363083 via openalex
- W3002354512 via openalex
- W3134885188 via openalex
- W3174133102 via openalex
- W3194419458 via openalex
- W3202177173 via openalex
- W3207063998 via openalex
- W4214754424 via openalex
- W4231335881 via openalex
- W4295895755 via openalex
- W4308775200 via openalex
- W6657076813 via openalex
- W6669857975 via openalex
- W6680637073 via openalex
- W6711628671 via openalex
Cited by (12)
- The Microbiota–Endometriosis Axis: An Immune–Endocrine Integration Model and Emerging Therapeutic Targets 2026
- Comparison of the Efficacy of Oral Elagorelix Versus Leuprolide Depot: Optimizing Natural Conception in Women with Endometrioma 2026
- Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States 2025
- The Multifactorial Pathogenesis of Endometriosis: A Narrative Review Integrating Hormonal, Immune, and Microbiome Aspects 2025
- The impact of endometriosis 2025
- Endometriosis in Adolescence: A Narrative Review of the Psychological and Clinical Implications 2025
- Personalized approach to infertility treatment in endometriosis: results of a prospective cohort study 2025
- Broadening horizons: microbiota as a novel biomarker and potential treatment for endometriosis 2025
- Efficacy and Safety of Oral Gonadotropin-Releasing Hormone Antagonist, Relugolix, in Endometriosis: A Meta-Analysis of Randomized Clinical Trials 2024
- Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023 2024
- Targeting c-MYC: a potential non-hormonal therapeutic approach for endometriosis treatment 2023
- IVF stimulation protocols and outcomes in women with endometriosis 2023
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-04T00:34:07.146298+00:00
License: CC0
· commercial use OK